257 related articles for article (PubMed ID: 27934879)
1. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
3. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
[TBL] [Abstract][Full Text] [Related]
4. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.
Liu N; Guo W; Shi Q; Zhuang W; Pu X; Chen S; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Gan W; Li D
Sci Rep; 2020 Oct; 10(1):16361. PubMed ID: 33004995
[TBL] [Abstract][Full Text] [Related]
5. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
6. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
7. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
8. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Ye H; Qin S; Li N; Lin M; Xu Y; Li X
Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
[TBL] [Abstract][Full Text] [Related]
9. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
[TBL] [Abstract][Full Text] [Related]
10. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
11. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
13. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
Kuthi L; Somorácz Á; Micsik T; Jenei A; Hajdu A; Sejben I; Imre D; Pósfai B; Kóczián K; Semjén D; Bajory Z; Kulka J; Iványi B
Pathol Oncol Res; 2020 Oct; 26(4):2123-2133. PubMed ID: 31955345
[TBL] [Abstract][Full Text] [Related]
15. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
[TBL] [Abstract][Full Text] [Related]
16. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
17. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.
Wang XT; Xia QY; Ni H; Wang ZY; Ye SB; Li R; Wang X; Lv JH; Shi SS; Ma HH; Lu ZF; Shen Q; Zhou XJ; Rao Q
Histopathology; 2016 Sep; 69(3):450-8. PubMed ID: 26844676
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
19. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
[TBL] [Abstract][Full Text] [Related]
20. RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases.
Di Mauro I; Dadone-Montaudie B; Sibony M; Ambrosetti D; Molinie V; Decaussin-Petrucci M; Bland V; Arbaud C; Cenciu B; Arbib F; Just PA; Derman J; Rioux-Leclercq N; Pedeutour F;
Genes Chromosomes Cancer; 2021 Nov; 60(11):772-784. PubMed ID: 34358382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
